Zobrazeno 1 - 10
of 243
pro vyhledávání: '"Xuezhi, Hao"'
Autor:
Siyu Lei, Linyan Tian, Lu Yang, Yaning Yang, Junling Li, Xingsheng Hu, Xuezhi Hao, Haiyan Xu, Yan Wang
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background Selective RET inhibitors have been approved by the Chinese government for the treatment of RET-rearranged non-small cell lung cancer. This study aimed to illustrate the efficacy and safety of selective RET inhibitors in a real-wor
Externí odkaz:
https://doaj.org/article/ea64b2d7a2634d2ea71250e7f13e4922
Autor:
Yan Li, Tongji Xie, Shouzheng Wang, Lin Yang, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Junling Li, Jianming Ying, Puyuan Xing
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Small-cell lung cancer (SCLC) transformation accounts for 3–14% of resistance in EGFR-TKI relapsed lung adenocarcinomas (LUADs), with unknown molecular mechanisms and optimal treatment strategies. We performed transcriptomic analyses (incl
Externí odkaz:
https://doaj.org/article/f112bbf4a98c456d876274631e76d926
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background In the era of second-generation ALK tyrosine kinase inhibitors (ALK-TKIs), there was a paucity of data regarding the progression patterns, resistant mechanisms, and subsequent therapeutic approaches for ALK-positive (ALK+) non-sma
Externí odkaz:
https://doaj.org/article/455fd9db100f4edfb8ffd74a06e877a5
Autor:
Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Shuyang Zhang, Xin Ai, Siyu Lei, Haiyan Xu, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3275-3281 (2023)
Abstract Background Although some targeted therapies have been shown to be effective in treating HER2‐altered non‐small cell lung cancer (NSCLC), the survival demands have not yet been met due to the high cost and limited availability. This study
Externí odkaz:
https://doaj.org/article/07bdfe03836746a9bfff7fd173e5061a
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Objectives Central nervous system (CNS) metastases including brain metastases (BM) and leptomeningeal metastases (LM) are frequent in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), and are correlated with
Externí odkaz:
https://doaj.org/article/46bc8c772ef64f8ca520f3c31f30bd2f
Autor:
Yuankai Shi, Jianhua Chen, Helong Zhang, Zhihong Zhang, Yiping Zhang, Zhehai Wang, Shucai Zhang, Jian Zhao, Chunling Liu, Xiuwen Wang, Yanqiu Zhao, Changlu Hu, Lei Yang, Xuezhi Hao, Lin Wang, Yunpeng Liu, Yan Yu, Jun Zhao, Mengzhao Wang, Liangming Zhang, Sanyuan Sun, Yanping Hu, Kangsheng Gu, Xiaosheng Hang, Jinlu Shan, Yu Zhang, Bangxian Tan, Weihua Yang, Runxiang Yang, Meimei Si, Huaize Geng, Hui Li, Xiaoyan Kang
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-12 (2023)
Abstract Background Iruplinalkib (WX-0593) is an anaplastic lymphoma kinase (ALK)/c-ros oncogene 1 (ROS1) tyrosine kinase inhibitor. Here we reported the single-arm, phase II study (INTELLECT) results of the efficacy and safety of iruplinalkib for AL
Externí odkaz:
https://doaj.org/article/fa1f8545777d42219ff4b4af29402825
Publikováno v:
Cancer Innovation, Vol 2, Iss 1, Pp 65-78 (2023)
Abstract Surgery followed by adjuvant chemotherapy is the standard of care for selected patients with early‐stage or locally advanced non‐small cell lung cancer (NSCLC). However, many of these patients still experience postoperative recurrence at
Externí odkaz:
https://doaj.org/article/95fad27fec7c4efca3bc313873132a1d
Autor:
Guangjian Yang, Yaning Yang, Runze Liu, Weihua Li, Haiyan Xu, Xuezhi Hao, Junling Li, Shuyang Zhang, Fei Xu, Siyu Lei, Yan Wang
Publikováno v:
Cancer Medicine, Vol 12, Iss 1, Pp 335-344 (2023)
Abstract Background Currently, survival benefit of immunotherapy in advanced non‐small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) is controversial, though it generally indicates poor response and activity. Compared with standar
Externí odkaz:
https://doaj.org/article/f9f7c6acb34447dcbd715589efc90172
Autor:
Yaning Yang, Xin Ai, Haiyan Xu, Guangjian Yang, Lu Yang, Xuezhi Hao, Ke Yang, Yuling Mi, Guizhen Wang, Shuyang Zhang, Siyu Lei, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 23, Pp 3295-3303 (2022)
Abstract Background The application of immune checkpoint inhibitors (ICIs) represents a breakthrough in the current landscape for the treatment of extensive‐stage small‐cell lung cancer (ES‐SCLC), but the real‐world outcome is limited. This s
Externí odkaz:
https://doaj.org/article/08e1341961ba43ef821000a62ab18405
Autor:
Fei Xu, Heng‐chi Chen, Haiyan Xu, Junling Li, Xuezhi Hao, Puyuan Xing, Jianming Ying, Yan Wang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 22, Pp 3105-3113 (2022)
Abstract Background Adjuvant chemotherapy (ACT) is considered for high‐risk patients in stage IB lung adenocarcinoma (LUAD). However, these risk factors are recognized as negative prognostic factors, not as predictors of ACT efficacy. This study ai
Externí odkaz:
https://doaj.org/article/95ff664282ff41a68f770c97c4977308